香港股市 已收市

Roche Holding AG (RHHVF)

Other OTC - Other OTC 延遲價格。貨幣為 USD。
加入追蹤清單
264.02+7.02 (+2.73%)
收市:01:36PM EST
全螢幕
正在載入互動式股價圖表...
  • Reuters

    UPDATE 1-Roche evaluates options for its lung disease drug

    Swiss drugmaker Roche said on Monday it is evaluating options for its lung disease drug Esbriet, which has seen declining sales due to competition from cheaper copycat versions. Generic versions of Esbriet began entering the market in the second quarter of 2022, impacting sales of Roche's drug. Sales of Esbriet fell 70% to 202 million Swiss francs ($229.42 million) in 2023.

  • Bloomberg

    Roche Explores Selling Lung Disease Drug Amid Buyer Interest

    (Bloomberg) -- Roche Holding AG is considering selling Esbriet, a lung disease drug that’s seen sales plummet amid competition from cheaper generics.Most Read from BloombergBYD’s New $233,450 EV Supercar to Rival Ferrari, LamborghiniStock Rally Stalls at Start of Data-Packed Week: Markets WrapFreddie Mercury’s London Residence Lists at £30 MillionJacob Rothschild, Financier and Philanthropist, Dies at 87Poland’s Famously Frank Top Diplomat Lands a Blow With Rebuff of RussiaThe Swiss pharmaceutic

  • Reuters

    Roche's Xolair reduces reactions to severe food allergies in study

    Xolair, a 20-year-old asthma drug sold by Roche and Novartis, significantly reduced allergic reactions in people with multiple severe food allergies in a late-stage trial, researchers reported on Sunday at a medical meeting. Based on the results, presented at the American Academy of Allergy, Asthma & Immunology meeting in Washington, the U.S. Food and Drug Administration approved the drug earlier this month for adults and children age 1 year or older for reducing allergic reactions that may occur from accidental exposure.